PROGNOSIS OF MYASTHENIA GRAVIS: A COMPREHENSIVE SYSTEMATIC REVIEW

Authors

  • Shabrina Maharani Faculty of Medicine, University of Riau, Indonesia Author
  • Latifah Ramadani Teluk Kuantan Regional General Hospital, Riau, Indonesia Author

DOI:

https://doi.org/10.61841/z1hjdw40

Keywords:

Myasthenia gravis, prognosis

Abstract

Background: The complex disease progression and treatment challenges affect the overall prognosis in myasthenia gravis (MG) patients. Recent advancements in managing MG have brought about significant progress in attaining complete stable remission  as the treatment objective. This study aims to systematically review the prognosis of MG in literatures of the last 10 years.

Methods: This systematic review complied with the PRISMA 2020 standards and focused on full-text English literature published between 2014 and 2024. Articles such as editorials and review papers from the same journal, as well as submissions lacking a DOI, were excluded from consideration. Literature was sourced from online platforms like PubMed and SagePub.

Result: We found 627 articles on PubMed and 810 articles on SagePub. Restricting our search to the past decade (20142024), PubMed presented 425 articles, whereas SagePub presented 309 articles. From these, we selected 5 papers meeting our criteria, with 2 from PubMed and 3 from SagePub.

Conclusion: Significant progress has been achieved in treating MG over the past decade. While some patients experience spontaneous remission, the majority require treatment with steroids or similar drugs. Other treatment modalities such as monoclonal antibody treatment, pulmonary function testing, and thymectomy can be employed to improve the prognosis of MG.

References

Alhaidar MK, Abumurad S, Soliven B, Rezania K. Current Treatment of Myasthenia Gravis. J Clin Med. 2022 Mar 14;11(6):1597.

Sieb JP. Myasthenia gravis: an update for the clinician. Clin Exp Immunol. 2014 Mar;175(3):408–18.

Mantegazza R, Antozzi C. When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies. Ther Adv Neurol Disord [Internet]. 2018 Jan 1 [cited 2024 Feb 16];11:1756285617749134. Available from: https://doi.org/10.1177/1756285617749134

Li Y, Yang S, Dong X, Li Z, Peng Y, Jin W, et al. Factors affecting minimal manifestation status induction in myasthenia gravis. Ther Adv Neurol Disord [Internet]. 2022 Jan 1 [cited 2024 Feb 18];15:17562864221080520. Available from: https://doi.org/10.1177/17562864221080520

van Gaal SC, English SW, Bourque PRJ, Zwicker JC. Pulmonary Function Testing in Elderly Patients Treated for a Myasthenia Gravis Exacerbation. The Neurohospitalist [Internet]. 2019 Apr 1 [cited 2024 Feb 18];9(2):79–84. Available from: https://doi.org/10.1177/1941874418811249

Narita T, Nakane S, Nagaishi A, Minami N, Niino M, Kawaguchi N, et al. Immunotherapy for ocular myasthenia gravis: an observational study in Japan. Ther Adv Neurol Disord [Internet]. 2023 Jan 1 [cited 2024 Feb 18];16:17562864231163819. Available from: https://doi.org/10.1177/17562864231163819

Muppidi S, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, et al. Long‐term safety and efficacy of eculizumab in generalized myasthenia gravis. Muscle and Nerve [Internet]. 2019 Jul [cited 2024 Feb 16];60(1):14–24. Available from: https://onlinelibrary.wiley.com/doi/10.1002/mus.26447

Wolfe GI, Kaminski HJ, Aban IB, Minisman G, Kuo HC, Marx A, et al. Randomized Trial of Thymectomy in Myasthenia Gravis. N Engl J Med [Internet]. 2016 Aug 11 [cited 2024 Feb 16];375(6):511–22. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1602489

Downloads

Published

2024-02-20

How to Cite

Maharani, S., & Ramadani, L. (2024). PROGNOSIS OF MYASTHENIA GRAVIS: A COMPREHENSIVE SYSTEMATIC REVIEW. Journal of Advanced Research in Medical and Health Science (ISSN 2208-2425), 10(2), 137-145. https://doi.org/10.61841/z1hjdw40

Similar Articles

1-10 of 20

You may also start an advanced similarity search for this article.